Clinical trial
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic…
NCT00061620 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00061620 |
|---|---|
| Title | Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies |
| Official title | Phase I Study of Continuous Infusion Schedule of (E)-2'-Deoxy-2'-(Fluoromethylene) Cytidine (Tezacitabine, FMdC) in Hematologic Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Chiron Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematologic Malignancies |
| Intervention type | Drug |
| Interventions | Tezacitabine (FMdC) |
| Enrollment | 19 |
| Start date | Sep 6, 2001 |
| Primary completion | Feb 12, 2004 |
| Completion | Feb 12, 2004 |
| First posted | Jun 2, 2003 |
| Last update posted | Nov 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: